Better Times Ahead For Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX)?

    SBUX Stock
    SBUX Stock

    BlackRock Fund Advisors has recently announced that it has increased stake in Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) by 0.83%. After grabbing 6.5 million shares, the institutional investor is now in possession of 53576.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.28% having worth around $27.95 million. Moreover, Armistice Capital LLC increased its share by 0.8 million to have a control over 6.2 million shares. And Morgan Stanley Smith Barney LLC (.. raised its holdings to 78837.0 shares by acquiring 2.75 million shares or 2.66% of the stake.

    Catalyst Pharmaceuticals Inc. (CPRX) concluded trading on 08/27/20 at a closing price of $3.22, with 1.86 million shares of worth about $6.0 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -8.26% during that period and on Thursday the price saw a loss of about -3.59%. Currently the company’s common shares owned by public are about 103.42M shares, out of which, 96.33M shares are available for trading.

    A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the CPRX stock and their offered price forecasts bring an average price target of $7.58. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $9.00 and could fall to a lowest price of $6.00. However, touching the estimated high of $9.00 would mean a gain of 64.22% for the stock.

    According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 8 times over the past 12 months. They bought 370,000 shares in 5 of the transactions. In 3 selling transactions, insiders dumped 350,000 shares.

    SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Catalyst Pharmaceuticals Inc. SPDR S&P Biotech ETF is currently holding 5.16 million shares of worth totaling $22.2 million. The company recently came selling 51723.0 shares which brought its stake up to 4.99% of the company’s outstanding shares. iShares Russell 2000 ETF, after selling 2.04 million shares, have now control over 1.98% of the stake in the company. It holds 95676.0 shares of worth $8.79 million.

    Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) started trading at $3.33, below -$0.01 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $3.22, or with a loss of -3.59%. Stock saw a price change of -8.26% in past 5 days and over the past one month there was a price change of -29.07%. Year-to-date (YTD), CPRX shares are showing a performance of -14.13% which decreased to -47.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.55 but also hit the highest price of $7.67 during that period. While comparing its average daily trading volume of 2.01 million shares, we see that about 1.86 million changed hands on the day. The stock is currently trading -14.57% below its 20-day simple moving average (SMA20), while that difference is down -26.54% for SMA50 and it goes to -25.46% lower than SMA200.

    BlackRock Fund Advisors acquired 6.5 million shares of Catalyst Pharmaceuticals Inc. having value of about $27.95 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 53576.0 shares in the company valued at close to $172514.72, or have control over 0.83% stake in the company. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) currently have 103.42M outstanding shares and institutions hold larger chunk of about 63.70% of that. Holding of mutual funds in the company is about 23.88% while other institutional holders and individual stake holders have control over 39.15% and 15.35% of the stake respectively.

    The stock has a current market capitalization of $337.04M and its 3Y-monthly beta is at 1.68. PE ratio of stock for trailing 12 months is 8.24, while it has posted earnings per share of $0.39 in the same period. It has Quick Ratio of 6.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CPRX, volatility over the week remained 4.63% while standing at 6.46% over the month.

    Analysts are in expectations that Catalyst Pharmaceuticals Inc. (CPRX) stock would likely to be making an EPS of $Catalyst Pharmaceuticals, Inc. in the current quarter, while forecast for next quarter ESPS is $3.22 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $RPRX which is $Copart, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Capri Holdings Limited in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 190.70% while it is estimated to increase by 4.27% in next year.

    Analysts at 6 brokerage firms have issued recommendations for the Catalyst Pharmaceuticals Inc. (CPRX)’s stock out of those 6 Wall Street analysts, 6 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

    Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on September 21, 2018 offering an Overweight rating for the stock and assigned a target price of to it. Coverage by Piper Jaffray stated Catalyst Pharmaceuticals Inc. (CPRX) stock as an Overweight in their note to investors on September 07, 2018, suggesting a price target of for the stock. On October 05, 2016, Piper Jaffray Upgrade their recommendations, while on April 26, 2016, Piper Jaffray Downgrade their ratings for the stock with a price target of $1. Stock get a Buy rating from ROTH Capital on September 30, 2014.


    Please enter your comment!
    Please enter your name here